Related Experiment Videos
ELA-max: A new topical lidocaine formulation
1The Pediatric Research in Emergency Therapeutics Program, Division of Pediatric Emergency Medicine, Clinical Pharmacology & Toxicology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. ran.goldman@sickkids.ca
The Annals of Pharmacotherapy
|April 1, 2004
Summary
ELA-max offers effective topical anesthesia for pediatric venipuncture, comparable to EMLA but with a quicker onset. Further research is needed to confirm its efficacy and safety for other pediatric procedures.
Area of Science:
- Pediatric Anesthesiology
- Dermatology
- Pharmacology
Background:
- Topical anesthesia in children presents clinical challenges.
- Effective pain management is crucial during pediatric procedures.
- Existing agents like EMLA have limitations.
Purpose of the Study:
- To evaluate the efficacy of a new lidocaine formulation, ELA-max, for local anesthesia in children.
- To compare ELA-max with the eutectic mixture of local anesthetics (EMLA).
Main Methods:
- A comprehensive literature search was conducted using MEDLINE (1966-November 2003) with terms ELA-max and EMLA.
- Bibliographies of relevant articles were reviewed for additional studies.
- Manufacturer data was sought for the most current information.
Main Results:
- ELA-max demonstrated comparable effectiveness to EMLA for venipuncture in pediatric patients.
- ELA-max exhibited a faster onset of action compared to EMLA.
- Reported adverse effects included transient blanching, redness, and erythema.
Conclusions:
- ELA-max shows promise as an effective topical anesthetic for pediatric venipuncture.
- Additional studies are required to ascertain the effectiveness of ELA-max for other pediatric painful procedures.
- Further investigation into the safety profile of ELA-max is warranted.